Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma by Abd El-Rehim, D M et al.
Expression and co-expression of the members of the epidermal
growth factor receptor (EGFR) family in invasive breast carcinoma
DM Abd El-Rehim
1, SE Pinder
1, CE Paish
1, JA Bell
1, RS Rampaul
2, RW Blamey
2, JFR Robertson
2, RI Nicholson
3
and IO Ellis*,1
1Department of Histopathology, The Breast Unit, Nottingham City Hospital NHS Trust and University of Nottingham, Hucknall Road, Nottingham NG5
1PB, UK;
2Department of Surgery, The Breast Unit, Nottingham City Hospital NHS Trust and University of Nottingham, Hucknall Road, Nottingham NG5
1PB, UK;
3Tenovus Institute, Cardiff, UK
The epidermal growth factor receptor (EGFR) family plays an important role in breast carcinogenesis. Much interest has been focused
recently on its members because of their potential role as prognostic indicators in breast cancer and their involvement in cancer
therapy. We have evaluated more than 1500 cases of invasive breast carcinoma immunohistochemically using tissue microarray
technology to examine the expression of EGFR family receptor proteins. We have found that 20.1 and 31.8% of cases were positive
for EGFR and c-erbB-2, respectively, and 45 and 45.1% of tumours overexpressed for c-erbB-3 and c-erbB-4, respectively. The
expression of either EGFR or c-erbB-2 was associated with other bad prognostic features and with poor outcome. Neither c-erbB-3
nor c-erbB-4 had any association with survival. c-erbB-2 had an independent prognostic effect on overall and disease-free survival
(DFS) in all cases, as well as in the subset of breast carcinoma patients with nodal metastases. Several hetero- and homodimeric
combinations have been reported between the EGFR members. Those dimers can evoke diverse signal transduction pathways with
variable cellular responses. We stratified cases according to their co-expression of receptors into distinct groups with different
receptor-positive combinations. Patients whose tumours co-expressed c-erbB-2 and c-erbB-3, as well as those whose tumours co-
expressed EGFR, c-erbB-2 and c-erbB-4 showed an unfavourable outcome compared with other groups, while combined c-erbB-3
and c-erbB-4 expression was associated with a better outcome. In cases showing expression of one family member only
(homodimers), we found a significant association between c-erbB-4 homodimer-expressing tumours and better DFS. In contrast,
patients with c-erbB-2 homodimer-expressing tumours had a significant poorer DFS compared with other cases. These data imply
that the combined profile expression patterns of the four receptor family members together provide more accurate information on
the tumour behaviour than studying the expression of each receptor individually.
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The epidermal growth factor receptor (EGFR) tyrosine kinase
family consists of four members: EGFR, c-erbB-2, c-erbB-3 and
c-erbB-4 (Gullick and Srinivasan, 1998). All share structural
homology consisting of an extracellular ligand-binding domain, a
transmembrane domain and an intracytoplasmic tyrosine kinase
domain (Mason and Gullick, 1995). There is a growing body of
evidence that this family is involved in breast cancer development
and progression (Gullick and Srinivasan, 1998). Previous studies of
EGFR and c-erbB-2 reported their association with characteristics
of poor prognosis. Epidermal growth factor receptor overexpression
was always associated with poor outcome, manifested in a short
overall survival and disease-free interval (Sainsbury et al, 1985;
Lewis et al, 1990; Toi et al, 1994; Tsutsui et al, 2002), high metastatic
potential (Sainsbury et al, 1987) and negative oestrogen receptor
(ER) status (Pilichowska et al, 1997; Tsutsui et al, 2002). The same
behaviour was also detected in tumours showing c-erbB-2 gene
amplification and/or overexpression, which was marked in high
tumour grade as well as short overall survival and disease-free
interval (Winstanley et al, 1991; Charpin et al, 1997; Suo et al, 2002).
Relatively less information has been reported about the other two
members: c-erbB-3 and c-erbB-4. Significant correlations have been
found between c-erbB-3 overexpression and tumour size (Travis
et al, 1996) and histological grade (Naidu et al, 1998). Studies on
c-erbB-4 expression have shown an association with well-diffe-
rentiated tumours (Kew et al, 2000; Suo et al, 2002) and positive ER
status (Suo et al, 2001). Some studies have found an association
with better survival (Pawlowski et al, 2000; Suo et al, 2002), while
others have reported an association with poor survival (Lodge et al,
2003) or no association with survival (Kew et al, 2000).
Most of the previous research has focused on investigating the
expression of individual members in relation to different
clinicopathological studies. However, a few studies have shown
that the co-expression of two or more members had an adverse
effect on breast cancer behaviour and outcome. The best example
for these findings is the reported adverse synergistic effect of EGFR
and c-erbB-2 expression on both prognosis (Osaki et al, 1992; Toi
et al, 1994; Suo et al, 2002) and metastasis (Brandt et al, 1999).
Such studies have evoked our interest to investigate the expression Received 31 March 2004; revised 23 July 2004; accepted 17 August 2004
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yof the four members together on a large number of invasive breast
carcinomas with long follow-up in order to shed light on any
potential prognostic implications.
MATERIALS AND METHODS
Patients
A consecutive series of 1944 cases of primary operable invasive
breast carcinoma from patients presenting between 1986 and 1998
and entered into the Nottingham Tenovus Primary Breast
Carcinoma Series were used. Data on histological grade (Elston
and Ellis, 1991), histological tumour type (Ellis et al, 1992),
vascular invasion (Pinder et al, 1994), tumour size, lymph node
stage and Nottingham Prognostic Index (NPI) (Galea et al, 1992)
are routinely assessed and recorded in the database. The NPI is
calculated using the following equation: NPI¼0.2 tumour size
(cm)þgrade (1–3)þlymph node stage (1–3). Patients are
assigned into three groups: good, moderate and poor. A score of
p3.4 indicates a good prognosis, 3.41–5.4 a moderate prognosis
and 45.4 a poor prognosis.
Patient age ranged from 18 to 70 years (mean age 53, median 54
years). Mean survival was 62 months (range 1–192 months).
Information on local, regional and distant recurrence and survival
is maintained on a prospective basis. Patients are followed up at 3-
month intervals initially, then 6 monthly and then annually, for a
median period of 58 months. The disease-free interval was defined
as the interval (in months) from the date of the primary surgical
treatment to the first loco-regional or distant recurrence. The
overall survival was taken as the time (in months) from the date of
the primary surgical treatment to the time of death. Oestrogen
receptor status was estimated immunohistochemically in 1805 of
the tumours; 553 (30.6%) were negative for ER expression, while
1252 (69.4%) carcinomas were ER positive.
Data for histological tumour type, grade and staging are
summarised in Tables 1 and 2.
Construction of the tissue microarray blocks
Breast cancer tissue microarrays were prepared as described
previously (Kononen et al, 1998; Camp et al, 2000; Torhorst et al,
2001). Haematoxylin and eosin (H&E) slides were obtained from
each available conventional tumour block and used as a guide for
selection of the most representative areas of the tumour. Tissue
microarrays were constructed by obtaining 0.6mm diameter
cylinders from the original blocks and re-embedding these cores
into the recipient block. Each case was sampled twice, from the
centre and the periphery of the tumour, to form an array of 100
cases per block. Histological tumour types and tumour grade are
summarised in Tables 1 and 2.
Immunohistochemistry
Immunohistochemical staining for the sections was performed
according to the avidin–biotin complex method. Tissue sections of
3mm thickness were taken from tissue array blocks. The initial
sections were stained with H&E to confirm the histological
diagnosis. Paraffin sections were dewaxed and then rehydrated.
To block the endogenous peroxidase, the rehydrated sections were
treated with 0.3% hydrogen peroxide in methanol for 10min. To
unmask the antigens, sections, with the exception of those for c-
erbB-2 and c-erbB-4, were microwaved in citrate buffer, pH 6 for a
total 20min. After the nonspecific staining had been blocked by
normal swine serum, sections were incubated with the primary
antibodies for between 50 and 60min. The antibodies used were
EGFR (clone EGFR.113, Novocastra, diluted at 1:10), c-erbB-2
(Dako, diluted at 1:250), c-erbB-3 (clone RTJ1, Novocastra,
diluted at 1:20), c-erbB-4 (clone HFR1, Neomarkers, diluted at
6:4) and ER (clone 1D5, Dako, diluted at 1:80). Sections were
incubated with the biotin-labelled secondary antibody (diluted
1:100) for 30min, then in avidin–biotin complex (diluted 1:100)
for a further 45min. 3-30Diaminobenzidine tetrahydrochloride was
used as the chromogen.
Controls
Positive and negative controls were included in each staining run.
Positive controls were myoepithelial cells of normal duct in normal
mammary gland for EGFR, renal tissue (proximal and distal
tubules) for c-erbB-3 and known positive cases of breast Table 1 Frequencies and percentage of histological tumour types
Tumour type No %
Invasive NST 1094 56.50
Tubular mixed 337 17.40
Medullary 46 2.40
Typical 5
Atypical 41
Lobular 220 11.40
Classical 141
Alveolar 2
Solid 6
Tubulo-lobular 6
Mixed 65
Tubular 79 4.10
Mucinous 26 1.30
Invasive cribriform 10 0.50
Invasive papillary 7 0.40
Mixed NST & lobular 65 3.40
Mixed NST & special type 41 2.10
Miscellaneous other types 14 0.70
Adenoid cystic 5
Metaplastic 3
Spindle cell tumour 1
Apocrine carcinoma 1
NST with clear cell features 1
NST with secretory features 1
NST with spindle cell element 1
Table 2 Frequencies and percentage of tumour grades, size, LN stage
and distant metastases
Grade No. %
1 367 18.9
2 647 33.4
3 925 47.7
LN stage No. %
N0 1231 63.6
N1 549 28.4
N2 156 8.1
Size No. %
p2cm 1220 62.9
42–5cm 685 35.3
45cm 36 1.9
Distant metastases No. %
M0 1701 88.8
M1 214 11.2
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obtained by omitting the primary antibodies.
Immunohistochemical scoring
The modified histochemical score (H-score) (McCarty et al, 1985)
was used as it includes a semiquantitative assessment of both the
intensity of staining and the percentage of positive cells. For the
intensity, a score of 0–3 corresponding to negative, weak,
moderate and strong positivity was recorded. In addition, the
percentage of positive cells at each intensity was estimated in %.
The H-score is calculated as (1 weak %þ2 moderate %þ3 
strongly stained %). The range of possible scores is thus 0–300.
Two cores were evaluated from each tumour. Each core was
scored individually, then the mean of the two readings was
calculated. Only the invasive carcinoma was assessed for staining.
Noninvasive cells such as stromal cells, normal epithelial cells,
benign lesions and carcinoma in situ were excluded from
assessment. If one core was uninformative (either lost or contained
no tumour tissues), the overall score applied was that of the
remaining core. Previous studies have validated the use of one core
to study the expression of tumour markers having heterogeneous
distribution (Camp et al, 2000; Torhorst et al, 2001). One observer
scored all cases, which were re-checked randomly by the same
investigator after a period of time. A good correlation was found
between the two estimations.
The cutoff points of expression were determined according to
frequency histograms. For all markers, tumours with 5% of the
neoplastic cells showing immunoreactivity were considered
positive, while those with less than 5% were classified negative.
Additionally, for c-ebB-3 and c-erbB-4, we considered the median
as a cutoff between weak and strong expression (150 and 100,
respectively). For ER, the cutoff point was taken at an H-score
of 20.
Statistical analysis
Association between the immunohistochemical findings and
different clinicopathological parameters was evaluated by w
2 test.
A P-value of o0.05 was considered to reflect a significant
relationship. Survival curves were calculated by the Kaplan–Meier
method. The differences between survivals were estimated by log-
rank test. Multivariate Cox regression analysis was used to evaluate
whether there was any independent prognostic effect of the
variables on disease-free interval or overall survival.
Figure 1 Immunohistochemical staining of breast carcinomas showing: (A) mixed cytoplasmic and membranous staining for EGFR, (B) membranous
staining for c-erbB-2, (C) cytoplasmic staining for c-erbb-3 and (D) cytoplasmic staining for c-erbb-4.
Expression and co-expression of EGFR
DM Abd El-Rehim et al
1534
British Journal of Cancer (2004) 91(8), 1532–1542 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yRESULTS
Epidermal growth factor receptor family protein
expression (Figure 1)
Epidermal growth factor receptor protein expression was
studied in 1584 cases. The expression was mainly cytoplasmic
and membranous and identified in 20.1% of cases. The expression
of c-erbB-2 protein was investigated in 1812 breast cancers, of
which 31.8% showed membranous immunoreactivity. For the 1499
cases stained with c-erbB-3, expression was mainly cytoplasmic,
with only 10.7% of cases considered negative, 44.3% weakly
positive and 45% strongly positive. In the 1513 cases stained for c-
erbB-4, predominantly cytoplasmic reactivity was identified in
79.3% of the tumours (34.2% weak and 45.1% strong positive),
while 20.7% were negative.
Significant positive associations were found between all EGFR
family members (Table 3), where 37.3% of HER1-positive tumours
Table 3 Positive significant associations among EGFR, c-erbB-2, c-erbB-3
and c-erbB-4
Variable EGFR c-erbB-2 c-erbB-3 c-erbB-4
EGFR
c-erbB-2 0.008
c-erbB-3 0.001 0.013
c-erbB-4 o0.001 0.040 o0.001
Table 4 EGFR family members expression in relation to clinicopathological features
EGFR ErbB2 ErbB3 ErbB4
Variable NP P -value NP P -value N Weak Strong P-value N Weak Strong P-value
Grade
1 248 29 242 86 51 111 101 82 74 106
2 459 59 429 173 69 226 193 138 166 194
V3 552 230 o0.0001 562 316 0.001 39 327 375 o0.0001 92 276 378 o0.0001
Total 1259 318 1233 575 159 664 669 312 516 678
Size
p1.5cm 449 88 450 188 58 219 234 113 184 213
41.5cm 810 230 0.007 785 386 0.127 101 446 435 0.6 199 332 466 0.183
Total 1259 318 1235 574 159 665 669 312 516 679
LN stage
1 791 195 794 342 115 403 406 207 339 391
2 367 94 343 178 31 202 215 83 136 233
3 98 29 0.717 97 51 0.19 12 60 45 0.015 21 41 54 0.015
Total 1256 318 1234 571 158 665 666 311 516 678
NPI
Good 448 57 440 151 79 204 193 135 159 182
Moderate 616 193 598 238 67 349 351 141 279 361
Poor 190 68 o0.0001 194 91 o0.0001 12 111 121 o0.0001 35 78 133 o0.0001
Total 1254 318 1232 570 158 664 665 311 516 676
LR
Yes 89 24 77 55 18 39 39 29 43 31
No 1153 291 0.782 1137 519 0.014 142 614 620 0.037 283 470 630 0.009
Total 1242 315 1214 574 160 653 659 312 513 661
RR
Yes 67 19 60 55 11 40 31 19 31 33
No 1175 295 0.658 1154 519 o0.0001 149 613 628 0.398 293 482 628 0.672
Total 1242 315 1214 574 160 653 659 213 513 661
VI
Yes 395 109 370 185 37 211 222 76 162 235
No 854 207 0.33 856 380 0.276 120 448 442 0.05 231 350 440 0.007
Total 1249 1226 565 157 659 664 307 512 675
DM
Yes 123 47 112 87 19 70 70 34 60 65
No 1118 267 0.01 1100 487 o0.0001 140 583 589 0.885 277 453 596 0.586
Total 1241 314 1212 574 159 653 659 311 513 661
Death
Yes 106 42 93 80 15 64 60 31 54 54
No 1136 273 0.009 1121 494 o0.0001 145 589 599 0.911 281 459 607 0.359
Total 1242 315 1214 574 160 653 659 312 513 661
ER status
Negative 304 164 335 208 45 202 202 59 182 206
Positive 942 153 o0.001 865 358 o0.001 110 459 466 0.933 247 330 470 o0.001
Total 1246 317 1200 566 155 661 668 306 512 676
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for HER1 (w
2¼7.01, P¼0.008); 54.7% of HER1-positive cases are
overexpressing to HER3 and 23.9% of HER3-overexpressing
tumours are HER1 positive (w
2¼14.54, P¼0.001); 55.8% of
HER1-positive tumours are overexpressing to HER4 and 24.3%
of HER4 overexpressing cancers are positive to HER1 (w
2¼17.60,
Po0.001); 50.1% of HER2-positive tumours are overexpressing to
HER3 and 34.9% of HER3-overexpressing cases are HER2 positive
(w
2¼8.66, P¼0.013); 49.5% of HER2-positive tumours are over-
expressing to HER4 and 34.6% of HER4-overexpressing tumours
are positive to HER2 (w
2¼6.41, P¼0.040); 64.9% of HER3-
overexpressing tumours are also overexpressing for HER4 and
63.7% of HER4-overexpressing tumours are also overexpressing
for HER3 (w
2¼351.90, Po0.001).
Association between EGFR family members and different
clinicopathological parameters
Table 4 shows the results of statistical analyses of the correlations
between different members and clinical and pathological variables.
Epidermal growth factor receptor expression was significantly
associated with higher tumour grade, increasing size, higher NPI,
the development of distant metastases and the incidence of death,
but inversely correlated with ER status. Regarding c-erbB-2,
immunoreactivity was significantly associated with poorer grade,
higher NPI, local and regional recurrence, distant metastases and
death, while inversely correlated to ER status. The expression of c-
erbB-3 showed a significant inverse association with local
recurrence, although it was significantly associated with poorer
grade, lymph node disease, higher NPI and the presence of
vascular invasion. The c-erbB-4 receptor expression showed a
significant paradoxical association with ER status and local
recurrence, while being significantly associated with poorer
histological grade, higher lymph node stage, NPI and the presence
of vascular invasion.
Survival analyses were performed comparing the expression of
the four markers in relation to both DFS and OS. We found that
EGFR expression was significantly associated with shorter disease-
free survival (DFS; P¼0.0265) and overall survival (P¼0.0035). c-
erbB-2 was also significantly correlated with poorer overall
survival (P¼0.0006) and DFS (P¼0.0001) (Figure 2A and B).
Neither c-erbB-3 nor c-erbB-4 showed a significant association
with DFS (P¼0.3401 and 0.2555, respectively) or overall survival
(P¼0.7462 and 0.7747, respectively).
Cox multivariate analyses showed that c-erbB-2 was not only
significantly related to DFS and overall survival, but also that its
predictive power was independent of histological grade, tumour
size, lymph node status and ER status in all patients as well as
patients with nodal spread. In node-negative patients, it had no
prognostic power in predicting OS, while its prognostic impact is
preserved in predicting DFS (Tables 5 and 6).
Co-expression of EGFR family members and their
association with OS and DFS
To define the frequency of dimers formation, we combined the
expression of the four markers in the 1406 cases of breast cancer in
which the results were available for all four members of the EGFR
family. In this part of the analysis, c-erbB-3- and c-erbB-4-
overexpressing cases were considered to be those showing
immunohistochemical positivity above the median level, while a
level below the median was considered as normal expression.
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Figure 2 (A) Epidermal growth factor receptor expression in relation to overall survival demonstrating survival differences between negative and positive
cases. (B) Epidermal growth factor receptor expression in relation to DFS showing longer DFS in negative patients. (C) c-erbB-2 in relation to overall
survival demonstrating survival differences between negative and positive cases. (D) c-erbB-2 in relation to DFS with better DFS in c-erbB-2-negative cases.
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Table 7.
The Kaplan–Meier estimates (Table 8) for the groups of
combined co-expression of two or more receptors and both of
overall and relapse-free survival showed a significant positive
Table 5 Cox multivariate regression analyses of variables in relation to disease-free survival (DFS) and overall survival (OS) in all patients
DFS Relative risk (95% CI) OS Relative risk (95 % CI)
P value P value
Grade 0.004 0.152
2 vs 1 0.23 1.353 (0.823–2.216) 0.203 1.995 (0.693–5.774)
3 vs 1 0.002 2.923 (1.462–5.844) 0.064 3.194 (0.935–10.908)
LN stage o0.001 o0.001
2 vs 1 0.879 1.035 (0.667–1.604) 0.592 0.837 (0.433–1.607)
3 vs 1 o0.001 3.143 (1.689–5.848) o0.030 2.549 (1.097–5.923)
Size
p1.5 vs 41.5 o0.034 1.449 (1.028–2.044) o0.062 1.688 (0.975–2.924)
NPI 0.024 0.13
Moderate vs good 0.032 0.520 (0.285–0.947) 0.483 1.410 (0.539–3.636)
Poor vs good 0.343 0.633 (0.243–1.629) 0.125 3.003 (0.773–12.218)
ER
Positive vs negative 0.004 0.651 (0.483–0.871) o0.001 0.492 (0.334–0.725)
EGFR
Positive vs negative 0.661 1.074 (0.780–1.479) 0.271 1.257 (0.837-1.888)
c-erbB-2
Positive vs negative 0.005 1.455 (1.121–1.887) 0.009 1.605 (1.125–2.289)
c-erbB-3 0.22 0.914
Weak vs negative 0.082 0.690 (0.454–1.048) 0.786 0.916 (0.483–1.723)
Strong vs negative 0.116 0.721 (0.454–1.145) 0.971 0.987 (0.494–1.972)
c-erbB-4 0.045 0.255
Weak vs negative 0.241 0.808 (0.566–1.154) 0.353 0.786 (0.473–1.306)
Strong vs negative 0.015 0.616 (0.416–0.912) 0.104 0.630 (0.361–1.099)
Table 6 Cox multivariate regression analyses of variables in relation to
overall survival and disease-free survival in patients with and without nodal
spread
DFS OS
P-value P value
LN-positive patients
Grade 0.050 0.120
LN stage
3 vs 2 o0.001 o0.001
Size 0.044 0.910
NPI 0.862 0.241
ER 0.009 0.001
EGFR 0.080 0.143
c-erbB-2 0.056 0.014
c-erbB-3 0.195 0.133
c-erbB-4 0.113 0.051
LN-negative patients
Grade 0.064 0.605
Size 0.214 0.033
NPI 0.133 0.298
ER
Positive vs negative
0.169
0.133
EGFR 0.343 0.947
c-erbB-2 0.031 0.144
c-erbB-3 0.395 0.432
c-erbB-4 0.357 0.954
Table 7 Frequencies of hetero- and homodimer formation among
different family members
Receptor expression No. %
EGFR/c-erbB-2 25 1.8
EGFR/c-erbB-3 28 2
EGFR/c-erbB-4 33 2.3
c-erbB-2/c-erbB-3 51 3.6
c-erbB-2/c-erbB-4 47 3.3
c-erbB-3/c-erbB-4 192 13.7
EGFR/c-erbB-2/c-erbB-3 17 1.2
EGFR/c-erbB-2/c-erbB-4 14 1
EGFR/c-erbB-3/c-erbB-4 63 4.5
c-erbB-2/c-erbB-3/c-erbB-4 108 7.7
EGFR/c-erbB-2/c-erbB-3/c-erbB-4 42 3
EGFR/EGFR 51 3.6
c-erbB-2/c-erbB-2 132 9.4
c-erbB-3/c-erbB-3 126 9
c-erbB-4/c-erbB-4 139 9.9
All negative 338 24
Total 1406 100
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and reduced OS (Figure 3A and B). The same relationship was also
noticed with combined expression of EGFR, c-erbB-2 and c-erbB-4
in relation to OS and DFS (Figures 4A and B) and for c-erbB-2
homodimers in relation to DFS (Figure 6) only. Conversely, the
combined expression of c-erbB-3 and c-erbB-4 was significantly
associated with a better OS and DFS (Figure 5A and B). Also, c-
erbB-4 homodimer was significantly associated with a better DFS
(Figure 7).
We were interested to see whether there was a significant
difference between c-erbB-2/c-erbB-3 heterodimer expression and
c-erbB-2/c-erbB-2 homodimer expression in relation to DSF and
OS. Although no significant differences were detected between
these two subgroups in relation to DFS (P¼0.6606) and OS
(P¼0.2501), we found that OS was worse in patients with tumours
expressing c-erbB-2/c-erbB-3 heterodimers compared to those
with tumours expressing c-erbB-2/c-erbB-2 homodimer (Figure 8).
DISCUSSION
In this study, expression of EGFR was identified in 20.1% of cases,
consistent with previous studies where EGFR expression has been
reported in 14–65% of breast cancer (Suo et al, 1998; Walker and
Dearing, 1999). c-erbB-2 overexpression was detected in 31.8%, in
line with previous reports showing 10–34% expression (Pauletti
et al, 1996; Ross and Fletcher, 1999). Expression of c-erbB-3 and c-
erbB-4 was 89.3% (45% strongly positive) and 79.3% (45.1%
strongly positive), respectively. These findings are also in
accordance with previous work which has identified c-erbB-3
expression in 65–95% of cases and c-erbB-4 in 58–82% of breast
cancers (Travis et al, 1996; Naidu et al, 1998; Kew et al, 2000; Suo
et al, 2002; Witton et al, 2003).
In this study, EGFR expression was significantly associated with
features recognised to reflect poor prognosis, including high
(poor) histological grade, high NPI score, negative ER status, larger
tumour size, the development of distant metastases and death.
Previous studies have reported the same relationships with tumour
grade (Suo et al, 1998), negative ER status and reduced survival
(Toi et al, 1990). Other studies have failed to find an association
with grade, tumour size and lymph node status (Lewis et al, 1990).
We have confirmed the previously reported significant correla-
tion identified between c-erbB-2-expressing tumours and poorer
tumour grade, ER negativity (Lovekin et al, 1991; Suo et al, 2002;
Witton et al, 2003; Zhang et al, 2003), high NPI score, local and
regional recurrence, distant metastases and death from breast
cancer. Our finding regarding the positive association between the
development of distant metastatic disease and c-erbB-2 expression
corroborates the findings of Tan et al (1997), who transfected c-
erbB-2 gene in the very low c-erbB-2-expressing MDA-MB-435
human breast cancer cell line and found that its overexpression
enhanced the metastatic potential of cancer cells.
A significant association between c-erbB-2 overexpression and
poor outcome in the form of short OS and DFS was found, as
previously observed in several series (Lovekin et al, 1991;
Table 8 Kaplan–Meier estimates of the associations between the
expression of heterodimers and homodimers in relation to overall survival
and disease free survival
OS DFS
Receptor co-expression No. P-value No. P-value
EGFR/c-erbB-2 25 25
Other cases 1359 0.7109 1358 0.8442
EGFR/c-erbB-3 28 28
Other cases 1356 0.2998 1355 0.7583
EGFR/c-erbB-4 33 33
Other cases 1351 0.1508 1350 0.7349
c-erbB-2/c-erbB-3 51 51
Other cases 1333 0.0354 1332 0.0423
c-erbB-2/c-erbB-4 46 46
Other cases 1338 0.7822 1337 0.7968
c-erbB-3/c-erbB-4 187 186
Other cases 1197 0.0114 1197 0.0634
EGFR/c-erbB-2/c-erbB-3 17 17
Other cases 1367 0.2825 1366 0.5716
EGFR/c-erbB-2/c-erbB-4 14 14
Other cases 1370 0.0024 1369 0.0054
EGFR/c-erbB-3/c-erbB-4 60 60
Other cases 1324 0.5969 1323 0.752
c-erbB-2/c-erbB-3/c-erbB-4 107 107
Other cases 1277 0.736 1276 0.6872
EGFR/c-erbB-2/c-erbB-3/c-erbB-4 42 42
Other cases 1342 0.0985 1341 0.4445
EGFR/EGFR 51 51
Other cases 1333 0.5 1332 0.3559
c-erbB-2/c-erbB-2 132 132
Other cases 1252 0.4423 1251 0.0175
c-erbB-3/c-erbB-3 125 125
Other cases 1259 0.613 1258 0.1289
c-erbB-4/c-erbB-4 131 131
Other cases 1253 0.4136 1252 0.0086
All negative 335 335
Other cases 1049 0.2859 1048 0.8463
Log rank P =0.0354
Log rank P =0.0423
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Figure 3 (A) c-erbB-2 and c-erbB-3 co-expression vs other cases in
relation to overall survival. (B) c-erbB-2 and c-erbB-3 co-expression vs
other cases in relation to DFS.
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yWinstanley et al, 1991; Witton et al, 2003). Winstanley et al (1991)
showed the independent prognostic effect in relation to OS. We
have also demonstrated that c-erbB-2 expression independently
predicted for poor OS and DFS in the whole population of breast
cancer patients as well as in those with node-positive disease. The
significant impact of c-erbB-2 overexpression/amplification on
poor outcome in patients with positive nodal metastases is well
established (Lovekin et al, 1991; O’Reilly et al, 1991).
In this series, c-erbB-3 expression was positively associated with
grade, lymph node metastases, poor NPI and vascular invasion,
while it was inversely associated with local recurrence. No relation
was identified with either ER status or survival. Previous reports
have recorded an association between c-erbB-3 overexpression and
poor prognostic features such as high grade (Naidu et al, 1998) and
lymph node spread (Lemoine et al, 1992). Some other studies have
previously noted an association with ER status, which we did not
find in the present large series. For example, Knowlden et al (1998)
reported a significant association with positive ER status and good
response to endocrine therapy for cases overexpressing c-erbB-3,
while others have failed to find associations with ER status
(Travis et al, 1996; Naidu et al, 1998). We have also, in the
present study, identified an inverse relation with local recurrence,
while the reverse was reported by Travis et al (1996), where
they found that moderate to strong expressing tumours were
more likely to develop local recurrence compared with weak
expressing and negative tumours (Travis et al, 1996). The
discrepancies in such relations may be partly explained by the
discovery of a c-erbB-3-soluble form, p85-soluble ErbB-3 (sErbB-
3), a potent negative regulator to heregulin, which inhibits
heregulin-induced phosphorylation of c-erbB-2, c-erbB-3 and c-
erbB-4 by competing for heregulin binding (Lee et al, 2001),
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Figure 4 (A) Epidermal growth factor receptor/c-erbB-2/c-erbB-4 co-
expression vs other cases in relation to overall survival. (B) Epidermal
growth factor receptor, c-erbB-2 and c-erbB-4 co-expression vs other
cases in relation to DFS.
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Figure 5 (A) c-erbB-3 and c-erbB-4 co-expression vs other cases in
relation to overall survival. (B) c-erbB-3 and c-erbB-4 co-expression vs
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antibodies and cutoffs used.
Very little is known with respect to the prognostic significance
of c-erbB-4 in breast cancer. In this study, we have demonstrated
that its overexpression was associated with higher grade, nodal
metastases, poor NPI and vascular invasion, and inversely
correlated with ER status and local recurrence. No significant
association was identified in relation to survival. Most studies
presented to date do not have congruent findings regarding the
prognostic effect of c-erbB-4 in breast cancer. Some studies linked
c-erbB4 overexpression with a well-differentiated phenotype (Kew
et al, 2000; Suo et al, 2002), positive ER status (Knowlden et al,
1998; Suo et al, 2001) and longer survival (Suo et al, 2002; Witton
et al, 2003). Another study associated overexpression with poor
survival in lymph node-positive cases (Lodge et al, 2003). The
significant inverse association between c-erbB-4 expression and
ER status observed in the present study has only been recorded in
one study by Vogt et al (1998), who demonstrated an inverse
association between c-erbB-4 gene amplification and ER status in
breast cancer (Vogt et al, 1998). These conflicting results may be
related to different scoring systems used, different definitions of
overexpression, the use of different antibodies, antigen retrieval
techniques and the heterogeneous populations of patients selected
for the studies. Variable responses may also be evoked by signals
generated from either c-erbB-4 homodimers or heterodimers with
other members, the level of which depends upon the context of
expression of other receptors. This may explain the association of
c-erbB-4 overexpression with some poor prognostic features in our
study, as a great many of cases co-expressed one or more other
receptors along with c-erbB-4. In support of this concept, a poor
prognostic association has been reported in relation to the co-
expression of c-erbB-2 and c-erbB-4 in childhood medulloblasto-
ma (Gilbertson et al, 1997). Another important factor in relation to
the diverse behaviour of c-erbB-4 is the type of isoform expressed
by the tumour. For example, the CYT-1 isoform mediates
proliferation as well as chemotaxis and survival signals, whereas
the CYT-2 isoform stimulates proliferation and growth only
(Junttila et al, 2000).
The hallmark of this family of growth factor receptors is the
ability of its members to act or function synergistically with
another receptor through dimerisation. ErbB-2 represents the
preferred heterodimerisation partner of all other receptors of the
family, and the preferred dimerisation partner of ErbB-2 is ErbB-3
(Tzahar et al, 1996). We found that 50.1% of c-erbB-2-expressing
tumours also overexpressed c-erbB-3 and that this heterodimer-
isation was significantly associated with poor OS and DFS. This
dimer, formed of ligand-deficient c-erbB-2 and kinase-deficient c-
erbB-3, is known to form the most potent signalling pair in terms
of growth and transformation (Alimandi et al, 1995; Wallasch et al,
1995). Therefore, the detection of the co-expression of these two
receptors may have more clinical and prognostic significance than
the detection of expression of each receptor separately.
Although there was a significant association between EGFR and
c-erbB-2 expression in this study, dimers formed of these receptors
alone are less frequent than other dimers; however, their combined
expression was more frequently common with c-erbB-3 and c-
erbB-4. Our study was one of few studies that addressed the
expression of the four receptors together compared to previous
studies that considered the expression of EGFR and c-erbB-2
ignoring the other receptors (Tsutsui et al, 2003).
In spite of the fact that the immunohistochemical expression of
both of EGFR and c-erbB-2 are linked with poor survival,
heterodimers formed of this pair had no significant association
with survival. It was surprising that EGFR and c-erbB-2 alone had
prognostic impacts whereas the combination of both was of no
significance, which disagree with literature (Toi et al, 1994; Suo
et al, 2002). We have no explanation for this contradiction, but
there are several factors that potentially contribute to these
inconsistent findings, including the use of different antibodies and
different cutoffs and definition of overexpression. Changing the
antibodies against EGFR and/or c-erbB-2 might overcome this
contradiction.
Cases co-expressing more than two family members, the
combination of EGFR, c-erbB-2 and c-erbB-4 had a highly
significant worse OS and DFS compared to other cases. The co-
expression of EGFR and c-erbB-2 has an additive adverse effect in
relation to survival (Toi et al, 1994; Suo et al, 2002).
Another interesting heterodimer identified in our study is that
of c-erbB-3 and c-erbB-4; cases which expressed both receptors
had a significantly better OS and DFS (trend) compared with other
dimers. We have no explanation for this finding; however, cell line
studies have shown that NDF induced mitogenesis in cells
expressing c-erbB-3 or c-erbB-4 but not transformation, which
was induced only when either EGFR or c-erbB-2 were coexpressed
with c-erbB-3 or c-erbB-4 (Zhang et al, 1996). This suggests that c-
erbB-3 and c-erbB-4 may activate signalling pathways that are
different from those activated by EGFR and c-erbB-2, or an
additional pathway may be needed to induce transformation.
In the present study, c-erbB-2 homodimers were significantly
associated with a poorer DFS. In spite of being a ligandless
receptor, cell line studies have shown that its overexpression
induced homodimerisation that was sufficient to induce growth,
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Figure 7 cerbB-4 homodimer expression vs other cases in relation to
DFS.
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dimer expression in relation to overall survival.
Expression and co-expression of EGFR
DM Abd El-Rehim et al
1540
British Journal of Cancer (2004) 91(8), 1532–1542 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
ymalignant transformation (Di Fiore et al, 1987; Brennan et al,
2000) and cell migration (Verbeek et al, 1998). Conversely, we
found that c-erbB-4 homodimers were significantly associated with
a better DFS compared with others. A previous study has similarly
recorded an association with a differentiated phenotype and with
better prognosis in breast cancer (Suo et al, 2002), and another
recent study has reported that breast cancer cases overexpressing
c-erbB-4 only were the best of all cases regarding outcome (Witton
et al, 2003).
The diversity identified in our study, in terms of survival,
between different heterodimers and homodimers may be useful in
subgrouping of breast cancer patients with significantly differing
outcome. These data suggest that the predictive value of EGFR
family overexpression may be optimised by combining informa-
tion about the expression of all of the family members, rather than
the assessment of a single receptor in isolation.
There are other essential components of the EGFR family
network, which have not been studied here; 10 or more ligands and
the proteins that are involved in EGFR family-induced pathways.
The receptors are conduits for the ligand-activated signalling
pathways and, although their expression levels clearly do contain
useful information, the precision of the analysis can only be
improved in the future by using antibodies for detection of such
proteins.
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